Initial case series describing children and adults with symptoms related to esophageal dysfunction and dense esophageal eosinophilia lead to recognition of a “new” disease, eosinophilic esophagitis (EoE). Clinical, basic, and…
Ikuo Hirano, MD, Editor Eosinophilic esophagitis (EoE) has emerged over the past two decades as an important cause of upper gastrointestinal symptoms in both adults and children. Defined as a…
Forthcoming Issues September 2014 Biologics of IBD Edward Loftus, Editor December 2014 Upper GI Bleeding Ian Gralnek, Editor March 2015 Gastroparesis Henry P. Parkman, Editor Recent Issues March 2014 Gastroesophageal…
Gary W. Falk, MD, MS, Editor Eosinophilic esophagitis (EoE) is a disease that was virtually unheard of 20 years ago. Yet, in recent years, there has been an explosive increase…
Despite the success of antitumor necrosis factor (TNF) therapy in Crohn’s disease, there remains a need for biologic therapy that targets other immune pathways of disease. Ustekinumab is a fully…
Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target…
Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including…
Biologic therapies, including the anti–tumor necrosis factor-α and cell adhesion molecule inhibitor drugs, have revolutionized the treatment of moderate-to-severe inflammatory bowel disease. Since the introduction of anti–tumor necrosis factor therapies,…
Anti-tumor necrosis factor-α (anti-TNF) agents are frequently used in the treatment of inflammatory bowel disease (IBD). Currently, there are 4 anti-TNF therapies that are Food and Drug Administration–approved for moderate…
In this review, the available data regarding the risk of lymphoma, skin cancers, and other malignancies associated with biological agents that are approved and those under investigation for use in…
